In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below
Each batch includes a COA with HPLC chromatogram and MS molecular weight confirmation
Researchers can explore additional educational resources through the Frontier Peptide Research Library, which features articles covering peptide biology, molecular signaling, laboratory methodologies, analytical chemistry, peptide handling, and current peptide research topics
Ghrelin plays a vital role in regulating energy balance, signaling to the brain when its time to eat

Key benefits Why people compare it 1 Increases intracellular NAD+ approximately 2-fold by blocking NNMT-mediated nicotinamide diversion 2 Activates SIRT1 longevity pathway via NAD+-dependent deacetylase activation 3 Reduces adipocyte size by approximately 40% with decreased DGAT1/DGAT2 expression 4 Produces 7% body weight reduction in DIO mice without appetite suppression 5 Improves glucose tolerance and reduces hepatic steatosis in preclinical obesity models 6 Preserves SAM levels for improved methylation capacity across tissues 7 Orally bioavailable small molecule (173 Da) requiring no injection or reconstitution 8 Shifts adipocyte metabolism from lipid storage to fatty acid oxidation (CPT1A/ACADM upregulation) Deep research About 5-Amino-1MQ 5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT) with a molecular weight of approximately 173 Da and a CAS registry number of 42675-71-0

Greenwald, R.A.) 285290 (CRC Press, Boca Raton, Florida, 1985)